Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 6:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 880 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Estring Clear all
Completed Phase 3 Interventional Results available

Study to Evaluate Equivalence of Estradiol Vaginal Cream 0.01% to Estrace® Cream 0.01% in Atrophic Vaginitis

NCT03294538
View directory record Official record
Conditions
Atrophic Vaginitis
Interventions
Generic Estradiol Vaginal Cream USP, 0.01%, Estrace® Vaginal Cream USP, 0.01%, Vehicle Vaginal Cream
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
30 Years to 75 Years · Female only
Enrollment
663 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
44
States / cities
Tucson, Arizona • La Mesa, California • Sacramento, California + 33 more
Source: ClinicalTrials.gov public record
Updated Dec 25, 2019 · Synced Sep 5, 2026, 6:56 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Plus Filgrastim in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00005810
View directory record Official record
Conditions
Prostate Cancer
Interventions
filgrastim, carboplatin, docetaxel, estramustine phosphate sodium
Biological · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
7
States / cities
San Francisco, California • Chicago, Illinois • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Sep 5, 2026, 6:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Characterize the Drug Levels of an Oral Contraceptive With and Without BMS-986166 in Healthy Female Participants of Childbearing Potential

NCT04934696
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986166, Oral contraceptive
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Sep 5, 2026, 6:56 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Effect of Race on Gonadotropin Responses

NCT00455962
View directory record Official record
Conditions
Premenopause, Healthy
Interventions
Estradiol steroid infusion, Progesterone steroid infusion
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Sep 5, 2026, 6:56 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Kronos Early Estrogen Prevention Study (KEEPS)

NCT00154180
View directory record Official record
Conditions
Menopause, Arteriosclerosis
Interventions
Conjugated equine estrogens 0.45 mg/day, Transdermal estradiol, 50 mcg/day, Micronized progesterone, 200 mg/day x 12 d/month, CEE , progesterone, estradiol patch or placebo for each, CEE, progesterone, transdermal patch or the placebo
Drug
Lead sponsor
Kronos Longevity Research Institute
Other
Eligibility
42 Years to 58 Years · Female only
Enrollment
728 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2012
U.S. locations
9
States / cities
Phoenix, Arizona • San Francisco, California • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2009 · Synced Sep 5, 2026, 6:56 PM EDT
Completed Phase 2 Interventional Results available

Fulvestrant in Treating Patients With Recurrent Ovarian Epithelial Cancer

NCT00617188
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Fulvestrant
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 27, 2017 · Synced Sep 5, 2026, 6:56 PM EDT
Completed Not applicable Interventional

A Study to Evaluate the Effects of Different Methods of Birth Control on the Drug Actions of Zidovudine (an Anti-HIV Drug) in HIV-Positive Women and to Compare Zidovudine Metabolism in Men and Women

NCT00000897
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
6
States / cities
San Francisco, California • Jacksonville, Florida • Albany, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2011 · Synced Sep 5, 2026, 6:56 PM EDT
Completed Phase 2 Interventional Results available

Bevacizumab Given With Either Anastrozole or Fulvestrant With Trastuzumab for Postmenopausal Metastatic Breast Cancer

NCT00405938
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasms
Interventions
Bevacizumab, Anastrozole, Fulvestrant
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older · Female only
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
11
States / cities
Fort Myers, Florida • Jacksonville, Florida • Orlando, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2021 · Synced Sep 5, 2026, 6:56 PM EDT
Completed Phase 2 Interventional Results available

Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.

NCT00921115
View directory record Official record
Conditions
Invasive Breast Cancer
Interventions
Fulvestrant, Anastrazole
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2023
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 18, 2023 · Synced Sep 5, 2026, 6:56 PM EDT
Recruiting Phase 2 Interventional

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

NCT06409390
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Taxotere, Cytoxan, Trastuzumab deruxtecan, Sacituzumab govitecan, Xeloda, Fulvestrant, Ribociclib, Abemaciclib
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Sep 5, 2026, 6:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess CYP3A4 Modulator, Oral Contraceptive, and pH Modifier Drug Interactions for ABI-H2158 in Healthy Adults

NCT04142762
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
ABI-H2158, Itraconazole, Rifampin, Midazolam, Ethinyl Estradiol / Levonorgestrel, Esomeprazole, Placebo matching oral contraceptive
Drug
Lead sponsor
Assembly Biosciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Sep 5, 2026, 6:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Randomized, Placebo-Controlled, Two-Period, Crossover Study to Evaluate the Effect of Lurasidone HCl on Oral Contraceptive Pharmacokinetics in Healthy Female Subjects

NCT00549666
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Lurasidone 40 mg, Placebo 40 mg, Ortho Tri-Cyclen
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 13, 2011 · Synced Sep 5, 2026, 6:56 PM EDT
Completed Phase 3 Interventional Results available

Multicenter Study to Evaluate Safety and Efficacy of WC3011 (Estradiol Vaginal Cream) in Postmenopausal Women

NCT01816139
View directory record Official record
Conditions
Vulvovaginal Atrophy
Interventions
Vehicle, WC3011 Estradiol Vaginal Cream
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
35 Years and older · Female only
Enrollment
576 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
48
States / cities
Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated May 8, 2022 · Synced Sep 5, 2026, 6:56 PM EDT
Completed Phase 2 Interventional Results available

Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

NCT01142401
View directory record Official record
Conditions
Metastatic Breast Carcinoma, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Bortezomib, Fulvestrant, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
21
States / cities
Farmington, Connecticut • New Haven, Connecticut • Weston, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2023 · Synced Sep 5, 2026, 6:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A STUDY TO ESTIMATE THE EFFECT OF PF-06651600 ON THE PHARMACOKINETICS (PK) OF ORAL CONTRACEPTIVE (OC)

NCT03608241
View directory record Official record
Conditions
Healthy Females
Interventions
PF-06651600, Ethinyl estradiol (EE) and levonogestrel (LN)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Coral Gables, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Sep 5, 2026, 6:56 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy and Safety Study for an Oral Contraceptive Containing Folate

NCT00468481
View directory record Official record
Conditions
Neural Tube Defects, Contraception, Oral Contraceptives (OC)
Interventions
Drospirenone/Ethinylestradiol/Methyltetrahydrofolate, Drospirenone/Ethinylestradiol (Yaz)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
385 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
9
States / cities
Anaheim, California • San Diego, California • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2014 · Synced Sep 5, 2026, 6:56 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Menopausal Sleep Fragmentation and Body Fat Gain

NCT03047330
View directory record Official record
Conditions
Menopause
Interventions
Estradiol withdrawal, Fragmented sleep
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Sep 5, 2026, 6:56 PM EDT
Terminated Phase 1 Interventional

Initiating Transdermal Estradiol Therapy in Turner's Syndrome

NCT00870220
View directory record Official record
Conditions
Turner's Syndrome
Interventions
Norditropin, Menostar 14mcg patch, Vivelle dot 25mcg patch
Drug
Lead sponsor
University of Chicago
Other
Eligibility
138 Months to 13 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
Chicago, Illinois • Baltimore, Maryland • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 10, 2014 · Synced Sep 5, 2026, 6:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating Premarin and Bazedoxifene Potential Interaction

NCT00745173
View directory record Official record
Conditions
Postmenopause
Interventions
Premarin
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
35 Years to 70 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2009 · Synced Sep 5, 2026, 6:56 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Estrogen for Treating Depression in Menopausal Women With Hot Flashes and Insomnia

NCT00227942
View directory record Official record
Conditions
Sleep Initiation and Maintenance Disorders, Depression
Interventions
Estrogen Replacement Therapy, Zolpidem, placebo
Drug
Lead sponsor
Hadine Joffe, MD
Other
Eligibility
40 Years to 60 Years · Female only
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 25, 2014 · Synced Sep 5, 2026, 6:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Norethindrone/Ethinyl Estradiol 0.4 mg/35 Mcg Chewable Tablets Under Non-Fasted Conditions

NCT01344369
View directory record Official record
Conditions
Healthy
Interventions
Norethindrone/Ethinyl Estradiol, FEMCON® Fe
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 29, 2011 · Synced Sep 5, 2026, 6:56 PM EDT
Not listed Not applicable Interventional

The LUTEAL Trial: Luteal Stimulation vs. Estrogen Priming Protocol

NCT04447872
View directory record Official record
Conditions
Infertility, Diminished Ovarian Reserve, IVF
Interventions
Timing of injectable gonadotropins
Procedure
Lead sponsor
Northwell Health
Other
Eligibility
20 Years to 45 Years · Female only
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2023 · Synced Sep 5, 2026, 6:56 PM EDT
Recruiting Not applicable Interventional

Silicone Gel vs. Estrogen Vaginal Cream for the Management of Genitourinary Syndrome of Menopause

NCT05672901
View directory record Official record
Conditions
Genitourinary Syndrome of Menopause
Interventions
StrataMGT, Estrace 0.01% Vaginal Cream
Device · Drug
Lead sponsor
Stratpharma AG
Industry
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Laguna Hills, California • Miami, Florida • Johns Creek, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Sep 5, 2026, 6:56 PM EDT
Recruiting Early Phase 1 Interventional

Identifying Oxytocin Deficiency in Pediatric Patients With Pituitary Disease

NCT07568509
View directory record Official record
Conditions
Arginine Vasopressin Deficiency, Oxytocin Deficiency, Pediatric Disease, Hypopituitarism
Interventions
Norethindrone Acetate-Ethinyl Estradiol
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
7 Years to 21 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 5, 2026, 6:56 PM EDT